Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Forge Biologics Inc.
Headquarters: Columbus, OH, United States of America
Website: https://www.forgebiologics.co...
Year Founded: 2020
Status: Private
BioCentury | Feb 15, 2025
Management Tracks
Robert Michael to succeed Gonzalez as Abbvie’s chair
Plus: Olazábal leaving Ysios and updates from Augustine and Prolific
BioCentury | Sep 10, 2024
Management Tracks
Vir names Jason O’Byrne CFO
Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more
BioCentury | Nov 13, 2023
Deals
Gene therapy CDMO Forge finds home in Ajinomoto via takeout
Best known for food and health products, Japanese company expands biopharma footprint with manufacturing capabilities
BioCentury | Aug 4, 2023
Finance
Biotechs that could enter the IPO queue as crossovers await liquidity
Among dozens of companies that raised crossover cash before markets turned sour, some may soon have what it takes to go public
BioCentury | Sep 14, 2022
Finance
Sept. 13 Quick Takes: Acelyrin heads for Phase III with $300M round
Plus note deals for Alnylam, Sarepta and updates from Rubius, Relay, Forge, Owkin, Ori and more
BioCentury | Jun 7, 2021
Management Tracks
New hires at Merck KGaA's neurology & immunology business; plus Repertoire, Kinnate, Allakos, Intercept and more
Amy Mahery, a 17-year veteran at Merck KGaA (Xetra:MRK), was named the pharma’s SVP and head of the neurology and immunology global business franchise; she was SVP and head of global market
BioCentury | May 13, 2021
Finance
Latest Garabedian-led Perceptive Xontogeny fund to deploy $515M in search of ‘transformational’ assets
New fund 2x the size of debut venture vehicle
BioCentury | Apr 29, 2021
Deals
Forge is the latest in a string of cell, gene therapy CDMO expansions: Data Byte
With its RA Capital-led $120 million series B round, Forge marks the latest cell and gene therapy-focused CDMO to announce significant expansions to its manufacturing operations. This year alone has
Items per page:
1 - 8 of 8